- Home
- CMPX vs NXP Comparison
CMPX vs NXP Comparison
Compare CMPX & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- NXP
- Stock Information
- Founded
- CMPX 2014
- NXP 1992
- Country
- CMPX United States
- NXP United States
- Employees
- CMPX N/A
- NXP N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- NXP Trusts Except Educational Religious and Charitable
- Sector
- CMPX Health Care
- NXP Finance
- Exchange
- CMPX Nasdaq
- NXP Nasdaq
- Market Cap
- CMPX 730.9M
- NXP 741.7M
- IPO Year
- CMPX N/A
- NXP N/A
- Fundamental
- Price
- CMPX $4.03
- NXP $14.48
- Analyst Decision
- CMPX Strong Buy
- NXP
- Analyst Count
- CMPX 7
- NXP 0
- Target Price
- CMPX $14.71
- NXP N/A
- AVG Volume (30 Days)
- CMPX 1.9M
- NXP 70.0K
- Earning Date
- CMPX 11-11-2025
- NXP 01-01-0001
- Dividend Yield
- CMPX N/A
- NXP 4.04%
- EPS Growth
- CMPX N/A
- NXP N/A
- EPS
- CMPX N/A
- NXP 0.54
- Revenue
- CMPX N/A
- NXP N/A
- Revenue This Year
- CMPX N/A
- NXP N/A
- Revenue Next Year
- CMPX N/A
- NXP N/A
- P/E Ratio
- CMPX N/A
- NXP $26.81
- Revenue Growth
- CMPX N/A
- NXP N/A
- 52 Week Low
- CMPX $1.27
- NXP $12.91
- 52 Week High
- CMPX $4.86
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- CMPX 53.07
- NXP 52.52
- Support Level
- CMPX $3.86
- NXP $14.41
- Resistance Level
- CMPX $4.86
- NXP $14.65
- Average True Range (ATR)
- CMPX 0.31
- NXP 0.11
- MACD
- CMPX -0.05
- NXP -0.02
- Stochastic Oscillator
- CMPX 38.43
- NXP 35.50
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.